MetaCap

Acumen Pharmaceuticals (ABOS) vs Dyadic International (DYAI)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Dyadic International (DYAI) has outperformed Acumen Pharmaceuticals (ABOS) over the past year, losing 68.8% versus a loss of 88.1%. Over five years, DYAI leads with a -92.2% price change compared with -97.7% for ABOS. Acumen Pharmaceuticals is the larger company by market cap ($13.5 million vs $11.5 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ABOS-88.12%DYAI-68.80%
+125%+13%-98%
Nov 21, 20251 yearNov 20, 2026
ABOS-98.11%DYAI-92.56%
+25%-40%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ABOS versus DYAI key metrics
MetricABOSDYAI
Share price$0.1865$0.287
Market cap$13.49M$11.51M
1-day change-3.52%-7.66%
YTD return-91.16%-69.47%
1-year return-88.12%-68.80%
5-year return-97.74%-92.24%
EPS (TTM)$-1.55$-0.21
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$3.09M
Revenue growth (YoY)—-11.59%
Net income (latest FY)$-121.33M$-7.36M
Gross margin—24.93%
Operating margin—-232.75%
Net margin—-238.31%
52-week high$3.60$1.60
52-week low$0.16$0.285
Distance from 52-week high-94.82%-82.06%
Analyst consensusstrong_buynone
Avg. price target upside+3975.07%+1816.38%
Average volume2.73M140.81K
Shares outstanding72.33M40.09M
Employees605
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • DYAI has outperformed ABOS by 19.3 percentage points over the past year.

About Acumen Pharmaceuticals

ABOS stock →

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 60 employees

About Dyadic International

DYAI stock →

Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5 employees

ABOS vs DYAI FAQ

Which is bigger, Acumen Pharmaceuticals or Dyadic International?

Acumen Pharmaceuticals (ABOS) is larger, with a market capitalization of $13.49M compared with $11.51M for Dyadic International (DYAI).

Which stock has performed better over the past year, ABOS or DYAI?

DYAI returned -68.80% over the past 12 months, compared with -88.12% for ABOS (price return, excluding dividends). Past performance does not predict future results.

Are Acumen Pharmaceuticals and Dyadic International in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons